Other functions - cancer prevention agent development program: early phase clinical research

Ended Awarded Last action

Contract number
HHSN261201200031I
Awardee
Awarding agency
Task orders
13 $15,760,448 obligated

Award facts

Opportunity
  • N01CN0501469 Solicitation number
Combined order value
  • $15,760,448 Current, with exercised options
  • $16,300,227 Potential, with all options
Last date to order 100% complete
Award type
Multiple award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
Full and Open Competition · 8 offers Negotiated Proposal / Quote
Pricing
Order Dependent (IDV only)

Award details come from SAM.gov/FPDS.

Task orders

Task order Ordering agency Obligated Awarded
Core infrastructure support for the cancer prevention agent development program 75N91019F00130 National Cancer Institute (NIH) $1,535,496
Clinical study of avmacol for detoxification of tobacco carcinogens in heavy smokers HHSN26100012 National Cancer Institute (NIH) $796,585
Topical therapies for treatment of CIN 2-3 HHSN26100011 National Cancer Institute (NIH) $763,665
R & d- core infrastructure support HHSN26100010 National Cancer Institute (NIH) $2,924,328
A prospective, single-arm, open-label, non-randomized, phase IIA trial of a nonavalent prophylactic HPV vaccine to… HHSN26100009 National Cancer Institute (NIH) $2,843,821
M4OC-prevent: metformin for oral cancer prevention HHSN26100008 National Cancer Institute (NIH) $812,958
R & d- core infrastructure support HHSN26100007 National Cancer Institute (NIH) $580,503
Phase II randomized placebo-controlled trial of prostvac (PSA-tricom) in patients with clinically localized cancer… HHSN26100006 National Cancer Institute (NIH) $2,513,111
Clinical study of the effect of combined treatment of aspirin and zileuton on biomarkers of tobacco-related… HHSN26100005 National Cancer Institute (NIH) $1,476,557
University of california at irvine clinical trial support HHSN26100004 National Cancer Institute (NIH) $151,603
Core infrastructure support HHSN26100003 National Cancer Institute (NIH) $470,308
The effect of intermittent versus continuous dose aspirin (ASA) in current smokers on nasal epithelium gene expression HHSN26100002 National Cancer Institute (NIH) $704,564
Other functions: core infrastructure support for cancer prevention agent development program: early phase clinical… HHSN26100001 National Cancer Institute (NIH) $186,949
Show all 13

Transactions

Action Obligated Date
Other Administrative Action P00007 $0
Other Administrative Action P00006 $0
Exercise an Option 5 $0
Exercise an Option 4 · Cancer prevention agent development program: early phase clinical research $0
Other Administrative Action 3 $0
Other Administrative Action 2 $0
Change Order 1 $0
Original award $0

Quick answers

Who was awarded contract HHSN261201200031I?

HHSN261201200031I was awarded to University Of Arizona by National Cancer Institute (National Institutes of Health) on September 24, 2012.

How much is contract HHSN261201200031I worth?

Orders under HHSN261201200031I have obligated $15,760,448. Their combined potential value, with all options, is $16,300,227.

How many orders have been placed under contract HHSN261201200031I?

13 orders have been placed under HHSN261201200031I, the latest on September 23, 2019.

Who can order from contract HHSN261201200031I?

HHSN261201200031I is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.

Is contract HHSN261201200031I part of a contract vehicle?

Yes. HHSN261201200031I is part of Cancer Prevention Agent Development Program 2012-2017.

Was contract HHSN261201200031I competed?

The extent of competition for HHSN261201200031I was full and open competition. The government received 8 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login